Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001213900-25-126161
- form_type
- 8-K
- ticker
- PHGE
- cik
- 0001739174
- company_name
- BiomX Inc.
- filed_at
- 2025-12-29T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:40.288431+00:00
- generated_at
- 2026-05-16T12:07:07.871225+00:00
- sec_items
- ["1.01", "3.02", "9.01"]
- event_type
- other_material
- sentiment
- negative
- materiality_score
- 0.7
- calibrated_materiality_score
- 0.7
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001213900-25-126161
- json_url
- https://secwatch.observer/filing/0001213900-25-126161.json
- markdown_url
- https://secwatch.observer/filing/0001213900-25-126161.md
- text_url
- https://secwatch.observer/filing/0001213900-25-126161.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1739174/000121390025126161/0001213900-25-126161-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1739174/000121390025126161/ea0271117-8k_biomx.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
DGAC
Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE
DISCIPLINED GROWTH ACQUISITION Corp
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On December 26, 2025, BiomX Inc., Inc., a Delaware corporation (the “Company” or “BiomX”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Company agreed to issue and sell, in a private placement transaction, an aggregate of 3,300 shares of the Company’s newly created Series Y Convertible Preferred Stock, par value $0.0001 per share (the “Series Y Preferred Stock”), with an aggregate stated value of $3.3 million, and warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for expected aggregate gross proceeds to the Company of $3.0 million, before deducting placement agent fees and other offering expenses.
Comparable filing
A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent
Filing page
SEC filing
CITR
CitroTech exchanges all Series A Preferred for Series C Convertible; BoltRock gets board rights
CitroTech Inc.
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On December 26, 2025, BiomX Inc., Inc., a Delaware corporation (the “Company” or “BiomX”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Company agreed to issue and sell, in a private placement transaction, an aggregate of 3,300 shares of the Company’s newly created Series Y Convertible Preferred Stock, par value $0.0001 per share (the “Series Y Preferred Stock”), with an aggregate stated value of $3.3 million, and warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for expected aggregate gross proceeds to the Company of $3.0 million, before deducting placement agent fees and other offering expenses.
Comparable filing
On May 28, 2026, CitroTech Inc., a Wyoming corporation (the “Company”), entered into Stock Exchange and Stockholders Agreements (the “Exchange Agreements”) with the holders (the “Holders”) of the Company’s outstanding Series A Preferred Stock
Filing page
SEC filing
SAGU
Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE
Shreya Acquisition Group
May 11, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On December 26, 2025, BiomX Inc., Inc., a Delaware corporation (the “Company” or “BiomX”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Company agreed to issue and sell, in a private placement transaction, an aggregate of 3,300 shares of the Company’s newly created Series Y Convertible Preferred Stock, par value $0.0001 per share (the “Series Y Preferred Stock”), with an aggregate stated value of $3.3 million, and warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for expected aggregate gross proceeds to the Company of $3.0 million, before deducting placement agent fees and other offering expenses.
Comparable filing
Private Units Subscription Agreement, dated May 6, 2026, by and between the Company and the Sponsor, a copy of which is attached as Exhibit 10.4 and incorporated herein by reference
Filing page
SEC filing
CLRB
Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data
Cellectar Biosciences, Inc.
May 8, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On December 26, 2025, BiomX Inc., Inc., a Delaware corporation (the “Company” or “BiomX”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Company agreed to issue and sell, in a private placement transaction, an aggregate of 3,300 shares of the Company’s newly created Series Y Convertible Preferred Stock, par value $0.0001 per share (the “Series Y Preferred Stock”), with an aggregate stated value of $3.3 million, and warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for expected aggregate gross proceeds to the Company of $3.0 million, before deducting placement agent fees and other offering expenses.
Comparable filing
pursuant to an additional securities purchase agreement with certain members of the executive management team of the Company (the “Management Purchase Agreement”
Filing page
SEC filing
XRN
Chiron Real Estate enters $100M preferred equity deal with Maewyn XRN LP
Chiron Real Estate Inc.
May 8, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On December 26, 2025, BiomX Inc., Inc., a Delaware corporation (the “Company” or “BiomX”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Company agreed to issue and sell, in a private placement transaction, an aggregate of 3,300 shares of the Company’s newly created Series Y Convertible Preferred Stock, par value $0.0001 per share (the “Series Y Preferred Stock”), with an aggregate stated value of $3.3 million, and warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for expected aggregate gross proceeds to the Company of $3.0 million, before deducting placement agent fees and other offering expenses.
Comparable filing
In connection with the Private Placement, on May 6, 2026, the Company and the Purchasers entered an Investor Rights Agreement.
Filing page
SEC filing
AIM
AIM ImmunoTech expects ~$4.2M gross from warrant inducement at $0.48/share; new warrants at $0.60
AIM ImmunoTech Inc.
May 8, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On December 26, 2025, BiomX Inc., Inc., a Delaware corporation (the “Company” or “BiomX”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Company agreed to issue and sell, in a private placement transaction, an aggregate of 3,300 shares of the Company’s newly created Series Y Convertible Preferred Stock, par value $0.0001 per share (the “Series Y Preferred Stock”), with an aggregate stated value of $3.3 million, and warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for expected aggregate gross proceeds to the Company of $3.0 million, before deducting placement agent fees and other offering expenses.
Comparable filing
On May 7, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a warrant exercise inducement offer letter agreement (the “Inducement Letter”) with holders (the “Holders”) of (i) Class A and Class B common stock purchase warrants issued on May 31, 2024
Filing page
SEC filing
AREB
American Rebel exchanges $1.77M preferred & note for ~5.97M common shares to Streeterville
AMERICAN REBEL HOLDINGS INC
May 8, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On December 26, 2025, BiomX Inc., Inc., a Delaware corporation (the “Company” or “BiomX”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Company agreed to issue and sell, in a private placement transaction, an aggregate of 3,300 shares of the Company’s newly created Series Y Convertible Preferred Stock, par value $0.0001 per share (the “Series Y Preferred Stock”), with an aggregate stated value of $3.3 million, and warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for expected aggregate gross proceeds to the Company of $3.0 million, before deducting placement agent fees and other offering expenses.
Comparable filing
On May 5, 2026, the Company entered into an Exchange Agreement (the “Note Exchange”) with Streeterville.
Filing page
SEC filing
AMPX
Amprius exchanges 7.1M public warrants for common stock; closing May 18, 2026
Amprius Technologies, Inc.
May 7, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: other_material
similar materiality
This filing
On December 26, 2025, BiomX Inc., Inc., a Delaware corporation (the “Company” or “BiomX”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Company agreed to issue and sell, in a private placement transaction, an aggregate of 3,300 shares of the Company’s newly created Series Y Convertible Preferred Stock, par value $0.0001 per share (the “Series Y Preferred Stock”), with an aggregate stated value of $3.3 million, and warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for expected aggregate gross proceeds to the Company of $3.0 million, before deducting placement agent fees and other offering expenses.
Comparable filing
On May 6, 2026, Amprius Technologies, Inc. (the “Company”) entered into Warrant Exchange Agreements (the “Exchange Agreements”) with certain institutional holders (the “Public Warrant Holders”) of the Company’s public warrants
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.